This finding may also explain the synergistic effects of CD39 blockade in combination with oxaliplatin chemotherapy,329 which itself promotes ATP release from apoptotic tumor cells and may therefore support purinergic receptor signaling under conditions in which released ATP is not quickly converted to adenosine. The gene discussed is ENTPD1; the disease is neoplasm.